Harwood Private Equity and Continental Investment Partners have jointly acquired Source BioScience plc through a public-to-private transaction for £65 million. The company provides laboratory services and products to the healthcare and clinical, life science research and biopharma industries. Services include diagnostic testing for cancer and other infectious disease, DNA sequencing and contract research activities, cryostorage and stability testing. Products include serology products for blood and tissue banking, life science research reagents and controlled environment chambers. Source BioScience operates ten facilities across the UK, Ireland, Germany and the US and has customers in over 90 countries. Dr Nick Ash is the CEO of Source BioScience and will continue the lead the company.